Travere Therapeutics vs Zai Lab
Travere Therapeutics reported revenue of $491 million in fiscal 2025, about the same as Zai Lab's $460 million in fiscal 2025. Travere Therapeutics' revenue grew 110.5% in its latest year, and Zai Lab's grew 15.3%. Travere Therapeutics had an operating margin of -12.8%, against -49.9% at Zai Lab.
Side by side
| Travere Therapeutics | Zai Lab | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $491M | $460M |
| Revenue growth | 110.5% | 15.3% |
| Revenue growth a year, last 5 years | 19.9% | 56.5% |
| Gross margin | 97.9% | 58.6% |
| Operating margin | −12.8% | −49.9% |
| Net margin | −5.2% | −38.1% |
| Free cash flow | — | −$159M |
| Free cash flow margin | — | −34.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 13.1% | 10.7% |
| Last close | $48.30 | $21.92 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $95.9 million | bought $65,804, sold $11.1 million |
| Piotroski F-score | 7 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Travere TherapeuticsZai Lab
Operating margin
Percent of revenue
Travere TherapeuticsZai Lab
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Travere TherapeuticsZai Lab
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Travere Therapeutics and Zai Lab pages.